15 research outputs found
Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells
Oligomers and polymers of flavan-3-ols (proanthocyanidins) are very abundant in the Mediterranean diet, but are poorly absorbed. However, when these polyphenols reach the colon, they are metabolised by the intestinal microbiota into various phenolic acids, including phenylpropionic, phenylacetic and benzoic acid derivatives. Since the biological properties of these metabolites are not completely known, in the present study, we investigated the effect of the following microbial phenolic metabolites: 3,4-dihydroxyphenylpropionic acid (3,4-DHPPA), 3-hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid (3,4-DHPAA), 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid and 4-hydroxyhippuric acid (4-HHA), on modulation of the production of the main pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6). The production of these cytokines by lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC) pre-treated with the phenolic metabolites was studied in six healthy volunteers. With the exception of 4-HHA for TNF-alpha secretion, only the dihydroxylated compounds, 3,4-DHPPA and 3,4-DHPAA, significantly inhibited the secretion of these pro-inflammatory cytokines in LPS-stimulated PBMC. Mean inhibition of the secretion of TNF-alpha by 3,4-DHPPA and 3,4-DHPAA was 84.9 and 86.4 %, respectively. The concentrations of IL-6 in the culture supernatant were reduced by 88.8 and 92.3 % with 3,4-DHPPA and 3,4-DHPAA pre-treatment, respectively. Finally, inhibition was slightly higher for IL-1beta, 93.1 % by 3,4-DHPPA and 97.9 % by 3,4-DHPAA. These results indicate that dihydroxylated phenolic acids derived from microbial metabolism present marked anti-inflammatory properties, providing additional information about the health benefits of dietary polyphenols and their potential value as therapeutic agents
Avaluació comparativa de la qualitat hospitalà ria a Catalunya: marca Q; exercici metodològic
Hospitals d’aguts; Qualitat i seguretat assistencial; Avaluació; Marca Q de qualitatHospitales de agudos; Calidad y seguridad asistencial; Evaluación; Marca Q de calidadAcute hospitals; Quality and safety of healthcare; Evaluation; Q-Mark in hospital care qualityLa qualitat i la seguretat assistencials són elements clau del Sistema Sanitari que cal garantir i maximitzar, tal com estableix el Pla de salut de Catalunya 2016-2020. En aquest sentit, una estratègia del Departament de Salut és la promoció de les millors prà ctiques en relació amb la qualitat i la seguretat assistencials mitjançant diverses iniciatives, com ara és el Projecte Marca Q de qualitat hospitalà ria, que té com a finalitat dissenyar una eina que permeti identificar la qualitat assistencial —en un sentit ampli—, i que sigui útil per poder avaluar comparativament els nivells de qualitat assolits pels hospitals d’aguts del sistema sanitari integral d'utilització pública de Catalunya (SISCAT). El propòsit d’aquesta eina serà identificar aquells aspectes del procés i dels resultats assistencials que són excel·lents, però també aquells que caldria millorar o corregir progressivament. Una condició essencial en el seu desenvolupament també ha de ser que incorpori l’opinió dels professionals de la salut i dels ciutadans en relació amb aquells aspectes i indicadors de qualitat assistencial més rellevants per a l’avaluació. En definitiva, es pretén comptar amb una nova eina que aporti valor afegit per a l’avaluació i la millora continuada de la qualitat assistencial. L’objectiu general d’aquest exercici metodològic ha estat desenvolupar una metodologia per construir un indicador combinat o sintètic de diversos indicadors de qualitat assistencial que permeti objectivar i valorar la qualitat de l’atenció hospitalà ria d’aguts a Catalunya.La calidad y la seguridad asistenciales son elementos clave del Sistema Sanitario que hay que garantizar y maximizar, tal y como establece el Pla de salut de Catalunya 2016-2020. En este sentido, una estrategia del Departament de Salut es la promoción de las mejores prácticas en relación con la calidad y la seguridad asistenciales mediante diferentes iniciativas, como es el Projecte Marca Q de qualitat hospitalà ria, que tiene como finalidad diseñar una herramienta que permita identificar la calidad asistencial —en un sentido amplio—, y que sea útil para poder evaluar comparativamente los niveles de calidad alcanzados por los hospitales de agudos del sistema sanitario integral de utilización pública de Cataluña (SISCAT). El propósito de esta herramienta será identificar aquellos aspectos del proceso y de los resultados asistenciales que son excelentes, pero también aquellos que habrÃa que mejorar o corregir progresivamente. Una condición esencial en su desarrollo también debe ser la incorporación de la opinión de los profesionales de la salud y de los ciudadanos en relación con aquellos aspectos e indicadores de calidad asistencial más relevantes para la evaluación. En definitiva, se pretende contar con una nueva herramienta que aporte valor añadido para la evaluación y la mejora continuada de la calidad asistencial. El objetivo general de este ejercicio metodológico ha sido desarrollar una metodologÃa para construir un indicador combinado o sintético de diversos indicadores de calidad asistencial que permita objetivar y valorar la calidad de la atención hospitalaria de agudos en Cataluña.The quality and safety of healthcare are key elements of the Health System that must be guaranteed and maximised, as established in the Pla de salut de Catalunya 2016-2020 (Catalan Health Plan of Catalonia 2016-2020. In this sense, one of the strategies of the Departament de Salut (the Ministry of Health) is the promotion of the best practices in regards to the quality and safety of healthcare by means of several initiatives, such as Projecte Marca Q de qualitat hospitalà ria (Q-Mark in hospital care quality project), which aims to create a tool that is able to assess the quality of healthcare —in a broad sense— and that is also useful to comparatively evaluate the quality levels reached by acute care hospitals belonging to the Integrated Public Use Healthcare System of Catalonia (SISCAT). The purpose of this tool will be to identify those aspects of the process and the healthcare results that are excellent, but also the ones that could be progressively improved or corrected. The incorporation of the opinion given by healthcare professionals and citizens in regards to those healthcare quality aspects and indicators that are more relevant for evaluation is a basic condition for the development of this tool. In other words, it is expected that this new tool will bring added value to the evaluation and continuous improvement of healthcare quality. The main objective of this methodological exercise has been the development of a methodology to elaborate a combined or synthetic indicator of several healthcare quality indicators that enables the objectification and valuation of the acute hospital care in Catalonia
CARACTERIZACIÓN DEL SERVICIO DE VENTA ONLINE DE MEDICAMENTOS EN LAS FARMACIAS CATALANAS DURANTE EL PERIODO 2015-2019.
Introducción: En julio de 2015, entró en vigor la normativa de venta a distancia de medicamentos de no prescripción a través de las páginas webs de las oficinas de farmacia, una nueva forma de dispensación y atención farmacéutica.
Objetivos: Conocer cuál ha sido el grado de implantación del servicio en las farmacias comunitarias de Cataluña, después de 5 años de inicio de la actividad.
Métodos: Estudio descriptivo de las páginas web activas de las farmacias de Cataluña durante el periodo 2015-2019, a partir de la revisión periódica y sistemática de dichas páginas web realizadas por el Departament de Salut.
Resultados: En 5 años, un 3,77% de las farmacias comunitarias catalanas disponen de página web activa de venta de medicamentos de no prescripción, porcentaje superior a la media española (2,03%). El año 2015 fue el que registró un mayor número de inicios de actividad, mientras que 2018 y 2019 fueron los que registraron menos inicios de actividad. Asimismo, en 2019 se registró el mayor número de suspensión de páginas web. En relación a las bajas, el 41,67% fueron a petición de la propia farmacia y el resto por resolución administrativa debido a un mantenimiento deficiente.
Conclusiones: El servicio de venta online de medicamentos de no prescripción a través de páginas web desde la farmacia comunitaria no ha conseguido una buena implantación desde su entrada en vigor. La tendencia actual es un descenso progresivo de la cobertura del servicio por no aportar un valor añadido, ni a la población ni al farmacéutico
CARACTERIZACIÓN DEL SERVICIO DE VENTA ONLINE DE MEDICAMENTOS EN LAS FARMACIAS CATALANAS DURANTE EL PERIODO 2015-2019.
Introducción: En julio de 2015, entró en vigor la normativa de venta a distancia de medicamentos de no prescripción a través de las páginas webs de las oficinas de farmacia, una nueva forma de dispensación y atención farmacéutica.
Objetivos: Conocer cuál ha sido el grado de implantación del servicio en las farmacias comunitarias de Cataluña, después de 5 años de inicio de la actividad.
Métodos: Estudio descriptivo de las páginas web activas de las farmacias de Cataluña durante el periodo 2015-2019, a partir de la revisión periódica y sistemática de dichas páginas web realizadas por el Departament de Salut.
Resultados: En 5 años, un 3,77% de las farmacias comunitarias catalanas disponen de página web activa de venta de medicamentos de no prescripción, porcentaje superior a la media española (2,03%). El año 2015 fue el que registró un mayor número de inicios de actividad, mientras que 2018 y 2019 fueron los que registraron menos inicios de actividad. Asimismo, en 2019 se registró el mayor número de suspensión de páginas web. En relación a las bajas, el 41,67% fueron a petición de la propia farmacia y el resto por resolución administrativa debido a un mantenimiento deficiente.
Conclusiones: El servicio de venta online de medicamentos de no prescripción a través de páginas web desde la farmacia comunitaria no ha conseguido una buena implantación desde su entrada en vigor. La tendencia actual es un descenso progresivo de la cobertura del servicio por no aportar un valor añadido, ni a la población ni al farmacéutico
Requisitos y condiciones para la publicidad de productos sanitarios dirigida al público
Publicitat; Productes sanitaris; PúblicPublicidad; Productos sanitarios; PúblicoAdvertising; Health products; AudienceD’acord amb la normativa en matèria de productes sanitaris i productes sanitaris de diagnòstic
in vitro, la publicitat d’aquests productes adreçada al públic està sotmesa a una sèrie de
limitacions i condicions i al control de les autoritats sanità ries de les comunitats autònomes que
exerceixen, entre d’altres actuacions, l’avaluació i l’autorització prèvies dels missatges
publicitaris que es volen difondre.De acuerdo con la normativa en materia de productos sanitarios y productos sanitarios de
diagnóstico in vitro, la publicidad de estos productos dirigida al público está sometida a una
serie de limitaciones y condiciones y al control de las autoridades sanitarias de las comunidades
autónomas que ejercen, entre otras actuaciones, la evaluación y la autorización previas de los
mensajes publicitarios que se desean difundir
Effect of cocoa powder in the prevention of cardiovascular disease: biological, consumption and inflammatory biomarkers. A metabolomic approach
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32392Numerous health benefits have been attributed to cocoa and its derived products in the last decade including antioxidant, anti-platelet and positive effects on lipid metabolism and vascular function. Inflammation plays a key role in the initiation and progression of atherosclerosis. However, cocoa feeding trials focused on inflammation are still rare and the results yielded are controversial. Health effects derived from cocoa consumption have been partly attributed to its polyphenol content, in particular of flavanols. Bioavailability is a key issue for cocoa polyphenols in order to be able to exert their biological activities. In the case of flavanols, bioavailability is strongly influenced by several factors, such as their degree of polymerization and the food matrix in which the polyphenols are delivered. Furthermore, gut has become an active site for the metabolism of procyanidins (oligomeric and polymeric flavanols). Estimation of polyphenol consumption or exposure is also a very challenging task in Food and Nutrition Science in order to correlate the intake of phytochemicals with in vivo health effects. In the area of nutrition, modern analytical techniques based on mass spectrometry are leading to considerable advances in targeted metabolite analysis and particularly in Metabolomics or global metabolite analysis. In this chapter we have summarized the most relevant results of our recent research on the bioavailability of cocoa polyphenols in humans and the effect of the matrix in which cocoa polyphenols are delivered considering both targeted analysis and a metabolomic approach. Furthermore, we have also summarized the effect of long-term consumption of cocoa powder in patients at high risk of cardiovascular disease (CVD) on the inflammatory biomarkers of atherosclerosis
Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells
Oligomers and polymers of flavan-3-ols (proanthocyanidins) are very abundant in the Mediterranean diet, but are poorly absorbed. However, when these polyphenols reach the colon, they are metabolised by the intestinal microbiota into various phenolic acids, including phenylpropionic, phenylacetic and benzoic acid derivatives. Since the biological properties of these metabolites are not completely known, in the present study, we investigated the effect of the following microbial phenolic metabolites: 3,4-dihydroxyphenylpropionic acid (3,4-DHPPA), 3-hydroxyphenylpropionic acid, 3,4-dihydroxyphenylacetic acid (3,4-DHPAA), 3-hydroxyphenylacetic acid, 4-hydroxybenzoic acid and 4-hydroxyhippuric acid (4-HHA), on modulation of the production of the main pro-inflammatory cytokines (TNF-alpha, IL-1beta and IL-6). The production of these cytokines by lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC) pre-treated with the phenolic metabolites was studied in six healthy volunteers. With the exception of 4-HHA for TNF-alpha secretion, only the dihydroxylated compounds, 3,4-DHPPA and 3,4-DHPAA, significantly inhibited the secretion of these pro-inflammatory cytokines in LPS-stimulated PBMC. Mean inhibition of the secretion of TNF-alpha by 3,4-DHPPA and 3,4-DHPAA was 84.9 and 86.4 %, respectively. The concentrations of IL-6 in the culture supernatant were reduced by 88.8 and 92.3 % with 3,4-DHPPA and 3,4-DHPAA pre-treatment, respectively. Finally, inhibition was slightly higher for IL-1beta, 93.1 % by 3,4-DHPPA and 97.9 % by 3,4-DHPAA. These results indicate that dihydroxylated phenolic acids derived from microbial metabolism present marked anti-inflammatory properties, providing additional information about the health benefits of dietary polyphenols and their potential value as therapeutic agents
Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease
Background: Epidemiologic studies have suggested that flavonoid intake plays a critical role in the prevention of coronary heart disease. Because atherosclerosis is considered a low-grade inflammatory disease, some feeding trials have analyzed the effects of cocoa (an important source of flavonoids) on inflammatory biomarkers, but the results have been controversial. Objective: The objective was to evaluate the effects of chronic cocoa consumption on cellular and serum biomarkers related to atherosclerosis in high-risk patients. Design: Forty-two high-risk volunteers (19 men and 23 women; mean 6 SD age: 69.7 6 11.5 y) were included in a randomized crossover feeding trial. All subjects received 40 g cocoa powder with 500 mL skim milk/d (C+M) or only 500 mL skim milk/d (M) for 4 wk. Before and after each intervention period, cellular and serum inflammatory biomarkers related to atherosclerosis were evaluated. Results: Adherence to the dietary protocol was excellent. No significant changes in the expression of adhesion molecules on T lymphocyte surfaces were found between the C+M and M groups. However, in monocytes, the expression of VLA-4, CD40, and CD36 was significantly lower (P = 0.005, 0.028, and 0.001, respectively) after C+M intake than after M intake. In addition, serum concentrations of the soluble endothelium-derived adhesion molecules P-selectin and intercellular adhesion molecule-1 were significantly lower (both P = 0.007) after C+M intake than after M intake. Conclusions: These results suggest that the intake of cocoa polyphenols may modulate inflammatory mediators in patients at high risk of cardiovascular disease. These antiinflammatory effects may contribute to the overall benefits of cocoa consumption against atherosclerosis. This trial was registered in the Current Controlled Trials at London, International Standard Randomized Controlled Trial Number, at controlled-trials.com as ISRCTN75176807
Effect of cocoa powder in the prevention of cardiovascular disease: biological, consumption and inflammatory biomarkers. A metabolomic approach
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32392Numerous health benefits have been attributed to cocoa and its derived products in the last decade including antioxidant, anti-platelet and positive effects on lipid metabolism and vascular function. Inflammation plays a key role in the initiation and progression of atherosclerosis. However, cocoa feeding trials focused on inflammation are still rare and the results yielded are controversial. Health effects derived from cocoa consumption have been partly attributed to its polyphenol content, in particular of flavanols. Bioavailability is a key issue for cocoa polyphenols in order to be able to exert their biological activities. In the case of flavanols, bioavailability is strongly influenced by several factors, such as their degree of polymerization and the food matrix in which the polyphenols are delivered. Furthermore, gut has become an active site for the metabolism of procyanidins (oligomeric and polymeric flavanols). Estimation of polyphenol consumption or exposure is also a very challenging task in Food and Nutrition Science in order to correlate the intake of phytochemicals with in vivo health effects. In the area of nutrition, modern analytical techniques based on mass spectrometry are leading to considerable advances in targeted metabolite analysis and particularly in Metabolomics or global metabolite analysis. In this chapter we have summarized the most relevant results of our recent research on the bioavailability of cocoa polyphenols in humans and the effect of the matrix in which cocoa polyphenols are delivered considering both targeted analysis and a metabolomic approach. Furthermore, we have also summarized the effect of long-term consumption of cocoa powder in patients at high risk of cardiovascular disease (CVD) on the inflammatory biomarkers of atherosclerosis